This article was originally published on PharmaTimes http://www.pharmatimes.com/news/keytruda_hits_endpoints_in_triple-negative_breast_cancer_1325630

Earlier this week, NICE released a draft guidance rejecting Keytruda when used in combo with Pfizer’s Inlyta (axitinib) to treat advanced renal cell carcinoma.

Related Posts